* If you want to update the article please login/register
"Interferon-u03b3 is a cytokine with limited evidence of benefit in cancer clinical trials to date. " In vitro, we show that IFN-u03b3 treatment resulted in the expression of key histocompatibility class-I genes and PD-L1 in prostate cancer cells. IFN-u03b3 systemic pretreatment enhanced the expression of HLA-A and reduced E-cadherin expression in the primary tumor, but more importantly in the metastatic site, leading to increased apoptosis and limited micrometastases in combination with paclitaxel therapy in control and monotherapy treatment groups," according to asymptomatic prostate cancer patients with chronic metastatic disease in both mice and monotherapy treatment groups.
Source link: https://doi.org/10.1038/s41598-022-10724-9
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions